RESEARCH / PARTICIPATIONBack to the library
← Find a study
Recruiting · registry status

Studying a plant-derived preparation for brain conditions

Researchers study a preparation based on compounds found in plants, investigating its use in conditions affecting brain cells.

Testing a treatment or activity · Study reference: NCT07360977

Plain-language introduction written with AI from the registry; not independently checked by a clinician. Read the original details below ↓

This registry record was last updated over six months ago, or its update date is missing. Recruitment may have changed. Confirm with the team before making plans.

Open the official registry record ↗

Follow this study

Looking for volunteers

Start (planned)
2026-01
Main measurements finished (planned)
2026-05-19
Study finished (planned)
2026-05-19

Planned dates can move. A study finishing does not tell us when a paper will be published.

No results summary has been confirmed in the registry records we imported. See connected papers below; we keep checking after recruitment ends.

Changes we have recorded
  • 2026-10-11 — recruiting

These are dates we observed a change, not necessarily the dates it happened.

Papers connected to this study

No connected paper has been found yet. The tracker checks the growing library for study identifiers and registry-linked publications.

Who can join?

Ages 1 year to 75 years · Does not accept healthy volunteers

These are starting points, not the full rules. The research team can tell you whether the study is right for your situation.

Read all the rules for taking part

Sex eligibility reported by registry: all

Inclusion Criteria: Inclusion Criteria for PD: * Male or female patients aged between 45-75 years old. * Clinical diagnosis of PD according to UK Brain Bank Criteria. * 3 months of clinical stability before study enrolment. * Anti-parkinsonian medication is fixed for at least 3 months prior to study entry. Inclusion Criteria for MS: * Male or female patients 18 years old or older. * Diagnosis of RR-MS according to McDonald criteria. * Expanded Disability Status Scale(EDSS) lower or equal to 5.5. * Stable disease for at least 30 days prior to study entry. * Stable disease-modifying therapy for at least 3 months prior to study entry. Common inclusion criteria for MS and PD: * No changes in drug treatment during 6 months-study treatment. * Patients understand and comply with the study procedure and are able to complete tests and examinations required by the project. * Written informed consent. Inclusion criteria for pediatric patients: * Eligible patients are those clinically stable; * Age range from 1 to 10, between 5 and 30 kg. * Patients not involved in other clinical trials. Exclusion Criteria: Exclusion criteria for PD and MS: * Absolute contraindications to Magnetic Resonance Imaging (MRI). * Concomitant neurological disease or severe co-morbidities able to influence outcomes such as spinal injury, cancer, dementia, or other central nervous system diseases such as stroke, epilepsy or psychiatric disorders; * Total score of Mini-Mental State Examination (MMSE)\<24. * Participating in other clinical trials. * Pregnant/lactating.
Full study name & original research details

Official study title

A Composition Comprising Glucoraphanin, Myrosinase and a Buffered Solution for Use in the Treatment of Neurodegenerative Diseases

Short title used by the registry

Myrosinase Bioactivated Gglucoraphanin for the Treatment of Neurodegenerative Diseases (GRA-MYR-ND)

Original description

Glucosinolates (GLs) are phytocompounds mainly found in the Cruciferae (Brassicacea) and Moringa oleifera plants. The hydrolysis of GLs by myrosinase led to the production of isothiocyanate (ITCs). ITCs consumption was associated with different health promoting effects, including to neuroprotective, anti-oxidant and anti-inflammatory capacities. In particular, they showed neuroprotective effects in experimental models of neurodegenerative diseases, including multiple sclerosis (MS) and Parkinson's disease (PD). From different GLs, different ITCs are originated. In particular, from glucoraphanin (GRA) the ITC sulforaphane (SFN) is obtained. The PI of the project is one of the proprietor of a patent (EP2908850B1) for the application of (Rs)-GRA with myrosinase in a buffered solution for the treatment of neurodegenerative diseases. The aim of this project is to evaluate the effects of the administration of bioactivated GRA in different cohorts of adult patients, affected by MS and PD, but also a cohort of pediatric patients affected by neuromuscolar and degenerative diseases. The effects of bioactivated (Rs)-GRA administration will be evaluated with a combination of clinical evaluations and a multiomic (metabolomic, genomic) approach.

Conditions reported: PARKINSON DISEASE (Disorder); Multiple Sclerosis (MS) - Relapsing-remitting; Pediatric Patients Affected by Neuromuscolar and Degenerative Diseases

Registry records for this study

Records are joined using registration identifiers. Titles alone do not establish that two studies are the same.

Study type
Interventional
Interventions
bioactivated GRA for adult patients; bioactivated GRA for pediatric patients
Phases
NA
Sponsor
IRCCS Centro Neurolesi Bonino Pulejo
Start date reported by registry
2026-01 (estimated)

Registry updated: 2026-01-22 · Status last verified by the registry submitter: 2025-12

Registry records retrieved 2026-10-13 (UTC). Individual records may have older updates. Recruitment and eligibility must be confirmed with the study team.

Contact the research team

Public study contacts supplied to the registry. Ask whether recruitment is still open and what participation involves.

Emanuela Mazzon · 09060128163 · emanuela.mazzon@irccsme.it

Study locations

Site status can differ from overall study status. “Status not reported” means local availability needs confirmation. Remote participation and travel arrangements must be checked with the team.

IRCCS Centro Neurolesi Bonino Pulejo

Messina, Italy

Recruiting

Facility not reported

Italy

Status not reported

The original descriptions and participation rules come from the registry. Participation is voluntary and does not guarantee benefit.